Melvin Weiss
Cardiovascular Disease · Hawthorne, NYNPI 1306849179
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Boston Scientific at 24.3% of the total. Reporting peaked in 2019 at $2,617 and has fallen 94.2% since, to $151 in 2025.
Across 103 payments — averaging $62.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Boehringer Ingelheim$815
- Johnson & Johnson$688
- Abbott$603
- AstraZeneca$508
- Novartis$384
- plus $2K from 15 others
Across 4 payments — averaging $5760.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$23K
What the payments were for
- Food & beverage$6,26498%
- Education$1592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 15 | $1,561 |
| Boehringer Ingelheim | 10 | $815 |
| Johnson & Johnson | 13 | $688 |
| Abbott | 7 | $603 |
| AstraZeneca | 5 | $508 |
| Novartis | 18 | $384 |
| Amgen | 5 | $261 |
| Biotronik Inc. | 2 | $259 |
| Novo Nordisk | 2 | $250 |
| Amarin Pharma, Inc. | 4 | $172 |
| Actelion Pharmaceuticals US, Inc. | 8 | $162 |
| Medtronic(2 entities) | 3 | $147 |
| Janssen Scientific Affairs, LLC | 1 | $137 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Pfizer | 1 | $124 |
| Portola Pharmaceuticals, LLC | 2 | $116 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Edwards Lifesciences | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$833
- JARDIANCE$741
- XARELTO$690
- WATCHMAN Access System$393
- JOT DX$266
- FARXIGA$250
- Ozempic$250
- Solia$150
- BioMonitor$150
- Acticor$150
- Edora$150
- Rivacor$150
- Vascepa$132
- ANDEXXA$128
- INJECTAFER$125
- ELIQUIS$124
- Repatha$124
- BRILINTA$120
- ENTRESTO$120
- Xience Sierra Coronary Stent System$113
How this compares
$6,423 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Hawthorne
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.